Developer docs
API playgroundTry for free, no card

Search company profiles

Travanti Pharma

Full company profile

uuid0035wmm

Namestring
Travanti Pharma
Legal namestring
AdminMed nanoBioSciences LLC
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Travanti Pharma, founded in 1997 and operating through its AdminMed nanoBioSciences LLC entity in Houston, TX, is a biotech company that develops microneedle array technology platforms for transdermal and intradermal drug and vaccine delivery. The core technology is the AdminPen hollow microneedle (MN) injection device, which the company first published on in 2010 and which has since been validated across more than 60 peer-reviewed publications spanning cancer immunotherapy, viral vaccines, transdermal drug delivery, and rheumatoid arthritis. The company's technology extends beyond the AdminPen into AdminStamp devices for vaccine and drug evaluation and the AdminPatch® microneedle array product family, giving it a multi-format platform covering preclinical and translational use cases.

The firm's business model centers on direct-to-consumer/evaluation sales of research-grade devices and consumables through e-commerce sites AdminMed.com and nanoBioSciences.com, with credit-card checkout and global shipping. Customers are primarily academic researchers, pharmaceutical companies, and healthcare/clinical groups conducting proof-of-concept and preclinical studies rather than clinical/therapeutic end users. The company monetizes via unit sales of devices and add-on services, pursues a 510(k) Class II medical-device regulatory pathway in the United States, and protects its position through registered trademarks (AdminPen™, AdminStamp, AdminPatch®) and granted patents on its hollow microneedle and array technologies.

The firm is small, operating with 1–10 employees, and is historically funded: prior rounds include a $1.7M investment from Spring Bay Ventures in 2005 and a $7.5M round from Prolog Ventures in 2006. There is no disclosed revenue, and the most recent public capital event dates to the 2006 round, leaving funding cadence and growth signals as material data gaps.

Short descriptiontext

Travanti Pharma (AdminMed nanoBioSciences) develops hollow microneedle (AdminPen, AdminStamp, AdminPatch®) drug and vaccine delivery platforms for academic researchers, pharmaceutical companies, and healthcare groups conducting preclinical studies, selling through global e-commerce storefronts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMendota, United States
HQ citystring
Mendota
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transdermal drug delivery, microneedle array devices, medical device manufacturing, vaccine delivery systems, biotech drug delivery
Industry2 codes
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Transdermal drug delivery devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeOne Time License
Description

Direct sales of AdminPen, AdminStamp, and AdminPatch microneedle devices through e-commerce platforms. Products sold for evaluation purposes to researchers and pharmaceutical companies.

adminmed.com
2Add-on Services
TypeProfessional Services
Description

Additional services offered alongside device products, including professional services and support.

adminmed.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
Pricing details1 tier
1AdminPen Devices - Hollow microneedle injection systems
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Multiple AdminPen device models available. Pricing available upon request or through product catalog.

adminmed.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1AdminPen
Description

Hollow microneedle injection device for painless, self-administered liquid drug delivery. AdminPen 600 is the flagship product with 16× amplified immunity for immunotherapies.

adminmed.com
+2 more records
Core offering1 text field

Travanti Pharma develops and commercializes microneedle-based drug delivery devices that enable painless, self-administered transdermal administration of liquid drugs, vaccines, and immunotherapies. Its product families — AdminPen hollow microneedle injectors, AdminStamp applicators, and AdminPatch solid microneedle arrays — are Class II medical devices sold directly via e-commerce to researchers, pharmaceutical companies, and healthcare providers for evaluation and therapeutic development. The platform is validated by 60+ peer-reviewed publications covering cancer immunotherapy, viral vaccines, photodynamic therapy, and rheumatoid arthritis treatment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 5-16× enhanced vaccine efficacy in cancer immunotherapies
+5 more records
Product overview1 text field

AdminMed nanoBioSciences LLC is a Houston-based medical device company manufacturing and selling microneedle array products for transdermal drug delivery. The product portfolio consists of three core device families and an add-on service: the AdminPen hollow microneedle injection devices (including the AdminPen 600), the AdminStamp devices, and the AdminPatch microneedle arrays, plus one add-on service offering. The AdminPen devices are designed for painless liquid injection with self-administration capability, compatible with standard syringes and pre-filled drug cartridges without requiring drug reformulation.

Product and service1 record
1AdminPen 600 Microneedle Liquid Injection Device
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vaxxas develops high-density microneedle array patches for vaccine and therapeutic delivery. It is the closest direct peer to Travanti's AdminPatch microneedle platform, targeting the same needle-free vaccine delivery use case with peer-reviewed clinical data.

TypeDirect peer
Description

Corium develops transdermal microneedle and patch-based drug delivery products. It is a direct peer in the transdermal/ microneedle device category, supplying pharma partners with patient-friendly administration platforms.

TypeDirect peer
Description

NanoPass manufactures the MicronJet hollow microneedle injection device for intradermal delivery of vaccines and biologics. It is a direct peer to AdminPen as a hollow-microneedle injection system used in vaccine and immunotherapy research and clinical applications.

TypeDirect peer
Description

Zosano Pharma develops microneedle patch systems for transdermal delivery of therapeutics. It is a direct peer in microneedle-based drug administration, pursuing similar indications and pharma partnership business model.

TypeBroad incumbent
Description

BD is a large medical-device incumbent with a broad drug-delivery portfolio that includes microneedle-related products and pre-filled injectors. It is a broad incumbent in the same delivery-device category rather than a niche specialist.

TypeDirect peer
Description

Kindeva (formerly 3M Drug Delivery Systems) develops microneedle-based and transdermal drug delivery platforms for pharma partners. It is a direct peer in microneedle/transdermal device technology serving vaccine and biologics developers.

TypeDirect peer
Description

PharmaJet manufactures needle-free jet injection devices for vaccines and therapeutics. It is a direct peer in the needle-free delivery category, competing for the same vaccine-developer and immunization-program customers as Travanti.

TypeEmerging player
Description

Micron Biomedical develops dissolvable microneedle arrays for vaccine and therapeutic delivery. It is an emerging player with partial overlap to Travanti's microneedle platform, focused specifically on dissolvable rather than hollow/solid arrays.

TypeBroad incumbent
Description

Hisamitsu (parent of Noven) is a major transdermal patch manufacturer with established pharma partnerships. It is a broad incumbent in transdermal delivery rather than a microneedle-only specialist, but competes for the same delivery-platform wallet.

TypeDirect peer
Description

LTS is a specialist contract developer and manufacturer of transdermal patches and microneedle systems. It is a direct peer offering drug-delivery device platforms to pharma partners across multiple therapeutic areas.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Travanti Pharma

Transdermal drug delivery devicestravantipharma.com

Travanti Pharma (AdminMed nanoBioSciences) develops hollow microneedle (AdminPen, AdminStamp, AdminPatch®) drug and vaccine delivery platforms for academic researchers, pharmaceutical companies, and healthcare groups conducting preclinical studies, selling through global e-commerce storefronts.

What Travanti Pharma does

Travanti Pharma, founded in 1997 and operating through its AdminMed nanoBioSciences LLC entity in Houston, TX, is a biotech company that develops microneedle array technology platforms for transdermal and intradermal drug and vaccine delivery. The core technology is the AdminPen hollow microneedle (MN) injection device, which the company first published on in 2010 and which has since been validated across more than 60 peer-reviewed publications spanning cancer immunotherapy, viral vaccines, transdermal drug delivery, and rheumatoid arthritis. The company's technology extends beyond the AdminPen into AdminStamp devices for vaccine and drug evaluation and the AdminPatch® microneedle array product family, giving it a multi-format platform covering preclinical and translational use cases.

The firm's business model centers on direct-to-consumer/evaluation sales of research-grade devices and consumables through e-commerce sites AdminMed.com and nanoBioSciences.com, with credit-card checkout and global shipping. Customers are primarily academic researchers, pharmaceutical companies, and healthcare/clinical groups conducting proof-of-concept and preclinical studies rather than clinical/therapeutic end users. The company monetizes via unit sales of devices and add-on services, pursues a 510(k) Class II medical-device regulatory pathway in the United States, and protects its position through registered trademarks (AdminPen™, AdminStamp, AdminPatch®) and granted patents on its hollow microneedle and array technologies.

The firm is small, operating with 1–10 employees, and is historically funded: prior rounds include a $1.7M investment from Spring Bay Ventures in 2005 and a $7.5M round from Prolog Ventures in 2006. There is no disclosed revenue, and the most recent public capital event dates to the 2006 round, leaving funding cadence and growth signals as material data gaps.

Travanti Pharma firmographics

Firmographics
Name
Travanti Pharma
Legal name
AdminMed nanoBioSciences LLC
Website
https://travantipharma.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
Travanti Pharma (AdminMed nanoBioSciences) develops hollow microneedle (AdminPen, AdminStamp, AdminPatch®) drug and vaccine delivery platforms for academic researchers, pharmaceutical companies, and healthcare groups conducting preclinical studies, selling through global e-commerce storefronts.
Ownership category
akta.pro rank

Travanti Pharma industry classification

Industry
Product category
Transdermal drug delivery devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Transdermal drug delivery
  • Microneedle array devices
  • Medical device manufacturing
  • Vaccine delivery systems
  • Biotech drug delivery

Where Travanti Pharma is headquartered

Location

Headquarters

HQ city
Mendota
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Travanti Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. Medical Device Sales: Direct sales of AdminPen, AdminStamp, and AdminPatch microneedle devices through e-commerce platforms. Products sold for evaluation purposes to researchers and pharmaceutical companies.
  2. Add-on Services: Additional services offered alongside device products, including professional services and support.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAdminPen Devices - Hollow microneedle injection systems

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Travanti Pharma product offering

Product offering

Core offering

Travanti Pharma develops and commercializes microneedle-based drug delivery devices that enable painless, self-administered transdermal administration of liquid drugs, vaccines, and immunotherapies. Its product families — AdminPen hollow microneedle injectors, AdminStamp applicators, and AdminPatch solid microneedle arrays — are Class II medical devices sold directly via e-commerce to researchers, pharmaceutical companies, and healthcare providers for evaluation and therapeutic development. The platform is validated by 60+ peer-reviewed publications covering cancer immunotherapy, viral vaccines, photodynamic therapy, and rheumatoid arthritis treatment.

Product overview

AdminMed nanoBioSciences LLC is a Houston-based medical device company manufacturing and selling microneedle array products for transdermal drug delivery. The product portfolio consists of three core device families and an add-on service: the AdminPen hollow microneedle injection devices (including the AdminPen 600), the AdminStamp devices, and the AdminPatch microneedle arrays, plus one add-on service offering. The AdminPen devices are designed for painless liquid injection with self-administration capability, compatible with standard syringes and pre-filled drug cartridges without requiring drug reformulation.

Differentiator

Problem solved

Functional benefit

Brands

  • AdminPen: Hollow microneedle injection device for painless, self-administered liquid drug delivery. AdminPen 600 is the flagship product with 16× amplified immunity for immunotherapies.
  • AdminStamp
  • AdminPatch

Products and services

  • AdminPen 600 Microneedle Liquid Injection Device

Quantifiable outcome

  • 5-16× enhanced vaccine efficacy in cancer immunotherapies
  • +5 more outcomes

Companies that use Travanti Pharma

Customer profile

Segments4 records

Ideal customer profiles4 records

Travanti Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Travanti Pharma partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Travanti Pharma competitors and assessment

Company assessment

Direct peers

  • Vaxxas: Vaxxas develops high-density microneedle array patches for vaccine and therapeutic delivery. It is the closest direct peer to Travanti's AdminPatch microneedle platform, targeting the same needle-free vaccine delivery use case with peer-reviewed clinical data.
  • Corium (transdermal drug delivery): Corium develops transdermal microneedle and patch-based drug delivery products. It is a direct peer in the transdermal/ microneedle device category, supplying pharma partners with patient-friendly administration platforms.
  • NanoPass Technologies: NanoPass manufactures the MicronJet hollow microneedle injection device for intradermal delivery of vaccines and biologics. It is a direct peer to AdminPen as a hollow-microneedle injection system used in vaccine and immunotherapy research and clinical applications.
  • Zosano Pharma: Zosano Pharma develops microneedle patch systems for transdermal delivery of therapeutics. It is a direct peer in microneedle-based drug administration, pursuing similar indications and pharma partnership business model.
  • Kindeva Drug Delivery: Kindeva (formerly 3M Drug Delivery Systems) develops microneedle-based and transdermal drug delivery platforms for pharma partners. It is a direct peer in microneedle/transdermal device technology serving vaccine and biologics developers.
  • PharmaJet: PharmaJet manufactures needle-free jet injection devices for vaccines and therapeutics. It is a direct peer in the needle-free delivery category, competing for the same vaccine-developer and immunization-program customers as Travanti.
  • LTS Lohmann Therapie-Systeme: LTS is a specialist contract developer and manufacturer of transdermal patches and microneedle systems. It is a direct peer offering drug-delivery device platforms to pharma partners across multiple therapeutic areas.

Broad incumbents

  • Becton Dickinson (BD): BD is a large medical-device incumbent with a broad drug-delivery portfolio that includes microneedle-related products and pre-filled injectors. It is a broad incumbent in the same delivery-device category rather than a niche specialist.
  • Hisamitsu Pharmaceutical (Noven): Hisamitsu (parent of Noven) is a major transdermal patch manufacturer with established pharma partnerships. It is a broad incumbent in transdermal delivery rather than a microneedle-only specialist, but competes for the same delivery-platform wallet.

Emerging players

  • Micron Biomedical: Micron Biomedical develops dissolvable microneedle arrays for vaccine and therapeutic delivery. It is an emerging player with partial overlap to Travanti's microneedle platform, focused specifically on dissolvable rather than hollow/solid arrays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Travanti Pharma social profiles

Digital presence

Travanti Pharma compliance and trust

Trust signal

Compliance1 record

Travanti Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Travanti Pharma leadership team

Management profile

Number of profiles

Travanti Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Travanti Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Travanti Pharma

What does Travanti Pharma do?

Travanti Pharma develops and commercializes microneedle-based drug delivery devices that enable painless, self-administered transdermal administration of liquid drugs, vaccines, and immunotherapies. Its product families — AdminPen hollow microneedle injectors, AdminStamp applicators, and AdminPatch solid microneedle arrays — are Class II medical devices sold directly via e-commerce to researchers, pharmaceutical companies, and healthcare providers for evaluation and therapeutic development. The platform is validated by 60+ peer-reviewed publications covering cancer immunotherapy, viral vaccines, photodynamic therapy, and rheumatoid arthritis treatment.

Is Travanti Pharma a public or private company?

Travanti Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Travanti Pharma founded?

Travanti Pharma was founded in 1997. It employs 1 to 10 people.

Where is Travanti Pharma based?

Travanti Pharma is headquartered in Mendota, United States, in the North America region.

How does Travanti Pharma make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are add-on Services.

Who are Travanti Pharma's main competitors?

Direct peers on record are Vaxxas, Corium (transdermal drug delivery), NanoPass Technologies, Zosano Pharma, Kindeva Drug Delivery, PharmaJet and LTS Lohmann Therapie-Systeme. Broad incumbents are Becton Dickinson (BD) and Hisamitsu Pharmaceutical (Noven). Micron Biomedical is listed as an emerging player.

Does Travanti Pharma have an API?

No public API is recorded for Travanti Pharma.

What industry is Travanti Pharma in?

Travanti Pharma's product category is Transdermal drug delivery devices. Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales